Unknown

Dataset Information

0

Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.


ABSTRACT: Next-generation sequencing (NGS) has enabled genome-wide personalized oncology efforts at centers and companies with the specialty expertise and infrastructure required to identify and prioritize actionable variants. Such approaches are not scalable, preventing widespread adoption. Likewise, most targeted NGS approaches fail to assess key relevant genomic alteration classes. To address these challenges, we predefined the catalog of relevant solid tumor somatic genome variants (gain-of-function or loss-of-function mutations, high-level copy number alterations, and gene fusions) through comprehensive bioinformatics analysis of >700,000 samples. To detect these variants, we developed the Oncomine Comprehensive Panel (OCP), an integrative NGS-based assay [compatible with <20 ng of DNA/RNA from formalin-fixed paraffin-embedded (FFPE) tissues], coupled with an informatics pipeline to specifically identify relevant predefined variants and created a knowledge base of related potential treatments, current practice guidelines, and open clinical trials. We validated OCP using molecular standards and more than 300 FFPE tumor samples, achieving >95% accuracy for KRAS, epidermal growth factor receptor, and BRAF mutation detection as well as for ALK and TMPRSS2:ERG gene fusions. Associating positive variants with potential targeted treatments demonstrated that 6% to 42% of profiled samples (depending on cancer type) harbored alterations beyond routine molecular testing that were associated with approved or guideline-referenced therapies. As a translational research tool, OCP identified adaptive CTNNB1 amplifications/mutations in treated prostate cancers. Through predefining somatic variants in solid tumors and compiling associated potential treatment strategies, OCP represents a simplified, broadly applicable targeted NGS system with the potential to advance precision oncology efforts.

SUBMITTER: Hovelson DH 

PROVIDER: S-EPMC4415141 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.

Hovelson Daniel H DH   McDaniel Andrew S AS   Cani Andi K AK   Johnson Bryan B   Rhodes Kate K   Williams Paul D PD   Bandla Santhoshi S   Bien Geoffrey G   Choppa Paul P   Hyland Fiona F   Gottimukkala Rajesh R   Liu Guoying G   Manivannan Manimozhi M   Schageman Jeoffrey J   Ballesteros-Villagrana Efren E   Grasso Catherine S CS   Quist Michael J MJ   Yadati Venkata V   Amin Anmol A   Siddiqui Javed J   Betz Bryan L BL   Knudsen Karen E KE   Cooney Kathleen A KA   Feng Felix Y FY   Roh Michael H MH   Nelson Peter S PS   Liu Chia-Jen CJ   Beer David G DG   Wyngaard Peter P   Chinnaiyan Arul M AM   Sadis Seth S   Rhodes Daniel R DR   Tomlins Scott A SA  

Neoplasia (New York, N.Y.) 20150401 4


Next-generation sequencing (NGS) has enabled genome-wide personalized oncology efforts at centers and companies with the specialty expertise and infrastructure required to identify and prioritize actionable variants. Such approaches are not scalable, preventing widespread adoption. Likewise, most targeted NGS approaches fail to assess key relevant genomic alteration classes. To address these challenges, we predefined the catalog of relevant solid tumor somatic genome variants (gain-of-function o  ...[more]

Similar Datasets

| S-EPMC5528527 | biostudies-other
| S-EPMC2832826 | biostudies-other
| S-EPMC7873485 | biostudies-literature
| S-EPMC9315443 | biostudies-literature
| S-EPMC4878677 | biostudies-literature